Merck Patent Gmbh

Ludwig Institute for Cancer Research Limited

Celldex Therapeutics Limited

Memorial Sloan Kettering Cancer Center

The University of North Carolina at Chapel Hill

Boston University

Famewave Ltd.

Antitope Limited

Oxford University Innovation Ltd

Intrexon Corporation

Amgen Research (Munich) Gmbh

Nissin Shokuhin Kabushiki Kaisha

Biovation Limited

Proclara Biosciences, Inc.

Vasgene Therapeutics, Inc

Francis Joseph Carr

Timothy David Jones

Lloyd J Old

Pilar Garin-Chesa

Thomas Paul Wallace

Wolfgang J Rettig

Anita Anne Hamilton

Graham Carter

Matthew Baker

Yaron R Hadari

Stephen Williams

William Joseph Harris

Tim Jones

John Watkins

Stephen D Gillies

Elisabeth Stockert

Sydney Welt

Robert George Edward Holgate

Michael Naso

Nelson Ruiz-Opazo

David Clemmons

Richard Fisher

Rajaraman Krishnan

Yair Sapir

Tehila Ben-Moshe

Laura A Maile

Gal Markel

Koen Hellendoorn

Jacob Schachter

Jeffrey Charles Way

Timothy Gareth Jones

Jeannick Cizeau

Robert Hofmeister

Nicholas Ronald Glover

Victoria L M Herrera

Benjamin Guy Davis

Joycelyn Entwistle

Valery Krasnoperov

Elizabeth M Mandel-Bausch

Laura Clare Alexandra Perry

Kathryn Lesley Armour

Kunio Kitamura

Marian Hanlon

Rona Ortenberg

Ilana Mandel

Ming Proschitsky

Eva Asp

Robert George E Holgate

Simon William Keen

Jones Tim

Robert G E Holgate

Birgit Kohleisen

Patrick Bäuerle

Michael Tal

Ulla Lenkkeri-Schütz

Christian Itin

Daniel Clive Anthony

Nicola Ruth Sibson

Denis Georges Bosc

Yan Yang

Nurit Rachamim

Sarit Samira

Ronald Ellis

Jeffrey C Way

Sreekala Mandiyan

Brett Robinson

Lida Kimmel

Richard Weldon

Sandra Jane Campbell

Robin Patrick Choudhury

Shahar Dotan

Robert GE Holgate

Richard A Fisher

Glen Christopher Macdonald

Fiona Adair

Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.

Anti-kit antibodies and uses thereof

Provided herein are compositions, methods and uses involving antibodies that specifically bind to MET, a receptor tyrosine kinase, and modulate the expression and/or activity of MET. Also provided are uses and methods for managing, treating, or preventing disorders, such as cancer. In one aspect, provided herein is a monoclonal antibody or antigen-binding fragment thereof that binds to the Sema/PSI domain of human MET. Also provided herein is a kit comprising an antibody or antigen-binding fragment provided herein. Also provided herein is a method of managing, protecting against, or treating cancer in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment provided herein.

Anti-MET antibodies and methods of use thereof

Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.

Humanized antibodies against CEACAM1

The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid deletion, insertion or substitution to remove a putative glycosylation signal. The invention further relates to such polypeptides that are also modified through additional amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability to bind and/or disaggregate amyloid. The invention further relates to the use of these g3p-modified polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.

Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal

Provided herein are novel compositions comprising anti-DEspR antibodies and fragments thereof derived from 6G8G7 and 7C5B2 anti-DEspR variant antibodies, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anti-DEspR antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-DEspR antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo non-invasive imaging and/or assessments.

Anti-DEspR monoclonal antibody targeted therapy and imaging for cancer and stroke

Methods of treating by administering anti-kit antibodies

Methods of treating a kit-associated cancer by administering anti-kit antibodies

The invention provides an antibody or fragment thereof that specifically binds to human endothelial vascular cell adhesion molecule-1 (VCAM-1), wherein the antibody or fragment thereof binds to the extracellular domain of VCAM-1, and wherein the antibody or fragment thereof binds to VCAM-1 when expressed on endothelial cells, wherein the antibody or fragment thereof is a human or humanized antibody, or fragment thereof.

Antibodies against CD106 (VCAM-1)

Humanized monoclonal antibodies (mAbs) or fragments thereof, to human Cluster of Differentiation 3 (CD3), which confer improved immune stimulation and stability, are disclosed. Pharmaceutical compositions comprising said mAbs and methods of treatment and optionally also prevention of diseases and disorders, such as autoimmune disorders, infectious diseases, and transplant rejection, that are susceptible to amelioration by binding to CD3, are also disclosed.

Humanized antibodies to cluster of differentiation 3 (CD3)

The invention provides an anti-CTLA4 antibody which inhibits the binding of CTLA4 to human B7, in particular, it inhibits binding of CTLA4 to human B7.1 and/or human B7.2. Specific antibodies are provided with specific variable region sequences as well as compositions comprising such antibodies for use in treating disease.

Humanised anti CTLA-4 antibodies

Polynucleotides encoding anti-kit antibodies

The present invention provides an antibody or antigen-binding fragment thereof that binds &#x3b1;&#x3b2;integrin, as well as methods of use in the treatment of diseases and disorders.

Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)

Growing community of inventors

Balmedie, United Kingdom

Francis Joseph Carr